Ets1 and Elk1 transcription factors regulate Cancerous Inhibitor of Protein phosphatase 2A expression in cervical and endometrial carcinoma cells

Transcription

Volumn 3, Issue 6, 2012, Pages 323-335

  Pallai, Rajash ^a   Bhaskar, Aishwarya ^a   Sodi, Valerie ^a   Rice, Lyndi M ^a  

^a LLC ^*  (United States)

Author keywords

Biomarkers; Cancer; CIP2A; Elk1; Ets1; p90; PP2A

Indexed keywords

CANCEROUS INHIBITOR OF PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE 2A; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BINDING AFFINITY; BINDING SITE; CARCINOMA CELL; CIP2A GENE; CONTROLLED STUDY; DNA PROTEIN COMPLEX; ENDOMETRIUM CARCINOMA; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; ONCOGENE; POINT MUTATION; PROMOTER REGION; PROTEIN BINDING; SITE DIRECTED MUTAGENESIS; UTERINE CERVIX CARCINOMA;

EID: 84872191898     PISSN: 21541264     EISSN: 21541272     Source Type: Journal    
DOI: 10.4161/trns.22518     Document Type: Article

References (54)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70; PMID:10647931; http:// dx.doi.org/10.1016/S0092-8674(00)81683-9.
2. Bishop JM, Weinberg RA, eds. Scientific American molecular oncology. New York: Scientific American, Inc., 1996.
3. Isaacs W, Kainu T. Oncogenes and tumor suppressor genes in prostate cancer. Epidemiol Rev 2001; 23:36-41; PMID:11588853; http://dx.doi.org/10.1093/ oxfordjournals.epirev.a000794.
4. Soo Hoo L, Zhang JY, Chan EKL. Cloning and characterization of a novel 90 kDa 'companion' autoantigen of p62 overexpressed in cancer. Oncogene 2002; 21:5006-15; PMID:12118381; http://dx.doi. org/10.1038/sj.onc.1205625.
5. Junttila MR, Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell Cycle 2008; 7:592-6; PMID:18256542; http://dx.doi.org/10.4161/ cc.7.5.5492.
6. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007; 130:51-62; PMID:17632056; http://dx.doi.org/10.1016/j.cell.2007.04.044.
7. Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia J, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 2008; 14:3722-8; PMID:18559589; http://dx.doi. org/10.1158/1078-0432.CCR-07-4137.
8. Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009; 15:5092-100; PMID:19671842; http://dx.doi. org/10.1158/1078-0432.CCR-08-3283.
9. Guenebeaud C, Goldschneider D, Castets M, Guix C, Chazot G, Delloye-Bourgeois C, et al. The dependence receptor UNC5H2/B triggers apoptosis via PP2Amediated dephosphorylation of DAP kinase. Mol Cell 2010; 40:863-76; PMID:21172653; http://dx.doi. org/10.1016/j.molcel.2010.11.021.
10. Shi FD, Zhang JY, Liu D, Rearden A, Elliot M, Nachtsheim D, et al. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 2005; 63:252-8; PMID:15538718; http:// dx.doi.org/10.1002/pros.20181.
11. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009; 101:793-805; PMID:19470954; http://dx.doi.org/10.1093/jnci/ djp103.
12. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S, et al. CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther 2010; 10:694-9; PMID:21068540; http:// dx.doi.org/10.4161/cbt.10.7.12895.
13. Vaarala MH, Väisänen MR, Ristimäki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010; 29:136-9; PMID:20964854; http:// dx.doi.org/10.1186/1756-9966-29-136.
14. Liu J, Wang X, Zhou G, Wang H, Xiang L, Cheng Y, et al. Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein. Gynecol Oncol 2011; 122:430-6; PMID:21575984; http:// dx.doi.org/10.1016/j.ygyno.2011.04.031.
15. Qu W, Li W, Wei L, Xing L, Wang X, Yu J. CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol 2012; 29:113-8; PMID:21140243; http:// dx.doi.org/10.1007/s12032-010-9768-9.
16. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011; 18:857-65; PMID:20842459; http://dx.doi.org/10.1245/s10434-010-1313-8.
17. Böckelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, et al. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 2011; 105:989-95; PMID:21897396; http://dx.doi. org/10.1038/bjc.2011.346.
18. Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK, et al. CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg 2012; 16:1037-47; PMID:22328001; http://dx.doi.org/10.1007/s11605-012-1828-3.
19. Böckelman C, Koskensalo S, Hagström J, Lundin M, Ristimäki A, Haglund C. CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther 2012; 13:289-95; PMID:22310977; http://dx.doi.org/10.4161/cbt.18922.
20. Böckelman C, Hagström J, Mäkinen LK, Keski-Säntti H, Häyry V, Lundin J, et al. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer 2011; 104:1890-5; PMID:21610708; http://dx.doi.org/10.1038/ bjc.2011.167.
21. Coenen EA, Zwaan CM, Meyer C, Marschalek R, Pieters R, van der Veken LT, et al. KIAA1524: A novel MLL translocation partner in acute myeloid leukemia. Leuk Res 2011; 35:133-5; PMID:20943269; http:// dx.doi.org/10.1016/j.leukres.2010.08.017.
22. Wang J, Li W, Li L, Yu X, Jia J, Chen C. CIP2A is over-expressed in acute myeloid leukemia and associated with HL60 cells proliferation and differentiation. Int Jnl Lab Hem 2011; 33:290-8; http://dx.doi. org/10.1111/j.1751-553X.2010.01288.x.
23. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 2011; 117:6660-8; PMID:21490338; http://dx.doi. org/10.1182/blood-2010-08-304477.
24. Lee J, Park EJ, Hwang JW, Oh JM, Kim H, Bae EK, et al. CIP2A expression is associated with synovial hyperplasia and invasive function of fibroblast-like synoviocytes in rheumatoid arthritis. Rheumatol Int 2012; 32:2023-30; PMID:21479604; http://dx.doi. org/10.1007/s00296-011-1927-6.
25. Baillat D, Bègue A, Stéhelin D, Aumercier M. ETS-1 transcription factor binds cooperatively to the palindromic head to head ETS-binding sites of the stromelysin-1 promoter by counteracting autoinhibition. J Biol Chem 2002; 277:29386-98; PMID:12034715; http:// dx.doi.org/10.1074/jbc.M200088200.
26. Baillat D, Laitem C, Leprivier G, Margerin C, Aumercier M. Ets-1 binds cooperatively to the palindromic Ets-binding sites in the p53 promoter. Biochem Biophys Res Commun 2009; 378:213-7; PMID:19022222; http://dx.doi.org/10.1016/j. bbrc.2008.11.035.
27. Babayeva ND, Wilder PJ, Shiina M, Mino K, Desler M, Ogata K, et al. Structural basis of Ets1 cooperative binding to palindromic sequences on stromelysin-1 promoter DNA. Cell Cycle 2010; 9:3054-62; PMID:20686355; http://dx.doi.org/10.4161/cc.9.14.12257.
28. Garvie CW, Pufall MA, Graves BJ, Wolberger C. Structural analysis of the autoinhibition of Ets-1 and its role in protein partnerships. J Biol Chem 2002; 277:45529-36; PMID:12221090; http://dx.doi. org/10.1074/jbc.M206327200.
29. Fitzsimmons D, Hodsdon W, Wheat W, Maira SM, Wasylyk B, Hagman J. Pax-5 (BSAP) recruits Ets protooncogene family proteins to form functional ternary complexes on a B-cell-specific promoter. Genes Dev 1996; 10:2198-211; PMID:8804314; http://dx.doi. org/10.1101/gad.10.17.2198.
30. Garvie CW, Hagman J, Wolberger C. Structural studies of Ets-1/Pax5 complex formation on DNA. Mol Cell 2001; 8:1267-76; PMID:11779502; http://dx.doi. org/10.1016/S1097-2765(01)00410-5.
31. Pufall MA, Graves BJ. Ets-1 flips for new partner Pax-5. Structure 2002; 10:11-4; PMID:11796106; http:// dx.doi.org/10.1016/S0969-2126(01)00701-8.
32. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, et al. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One 2011; 6:e17979; PMID:21445343; http://dx.doi. org/10.1371/journal.pone.0017979.
33. Selga E, Noé V, Ciudad CJ. Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis. Biochem Pharmacol 2008; 75:414-26; PMID:17945194; http://dx.doi.org/10.1016/j. bcp.2007.08.034.
34. Pallai R, Simpkins H, Chen J, Parekh HK. The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene. Gene 2010; 459:11-23; PMID:20338228; http://dx.doi. org/10.1016/j.gene.2010.03.006.
35. Shore P, Sharrocks AD. The ETS-domain transcription factors Elk-1 and SAP-1 exhibit differential DNA binding specificities. Nucleic Acids Res 1995; 23:4698-706; PMID:8524663; http://dx.doi.org/10.1093/ nar/23.22.4698.
36. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003; 303:11-34; PMID:12559563; http://dx.doi.org/10.1016/S0378-1119(02)01156-3.
37. Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer 2003; 2:29; PMID:12971829; http:// dx.doi.org/10.1186/1476-4598-2-29.
38. Kodandapani R, Pio F, Ni CZ, Piccialli G, Klemsz M, McKercher S, et al. A new pattern for helix-turn-helix recognition revealed by the PU.1 ETS-domain-DNA complex. Nature 1996; 380:456-60; PMID:8602247; http://dx.doi.org/10.1038/380456a0.
39. Treisman R. The serum response element. Trends Biochem Sci 1992; 17:423-6; PMID:1455511; http:// dx.doi.org/10.1016/0968-0004(92)90013-Y.
40. Shore P, Bisset L, Lakey J, Waltho JP, Virden R, Sharrocks AD. Characterization of the Elk-1 ETS DNA-binding domain. J Biol Chem 1995; 270:5805-11; PMID:7890710; http://dx.doi.org/10.1074/ jbc.270.11.5805.
41. Sharrocks AD. Complexities in ETS-domain transcription factor function and regulation: lessons from the TCF (ternary complex factor) subfamily. The Colworth Medal Lecture. Biochem Soc Trans 2002; 30:1-9; PMID:12023815; http://dx.doi.org/10.1042/ BST0300001.
42. Shaw PE, Saxton J. Ternary complex factors: prime nuclear targets for mitogen-activated protein kinases. Int J Biochem Cell Biol 2003; 35:1210-26; PMID:12757758; http://dx.doi.org/10.1016/S1357-2725(03)00031-1.
43. Boros J, Donaldson IJ, O'Donnell A, Odrowaz ZA, Zeef L, Lupien M, et al. Elucidation of the ELK1 target gene network reveals a role in the coordinate regulation of core components of the gene regulation machinery. Genome Res 2009; 19:1963-73; PMID:19687146; http://dx.doi.org/10.1101/gr.093047.109.
44. Boros J, O'Donnell A, Donaldson IJ, Kasza A, Zeef L, Sharrocks AD. Overlapping promoter targeting by Elk-1 and other divergent ETS-domain transcription factor family members. Nucleic Acids Res 2009; 37:7368-80; PMID:19789270; http://dx.doi. org/10.1093/nar/gkp804.
45. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev 2007; 21:1882-94; PMID:17652178; http://dx.doi.org/10.1101/ gad.1561707.
46. Shukla AA, Jain M, Chauhan SS. Ets-1/Elk-1 is a critical mediator of dipeptidyl-peptidase III transcription in human glioblastoma cells. FEBS J 2010; 277:1861-75; PMID:20236318; http://dx.doi.org/10.1111/j.1742-4658.2010.07603.x.
47. Choi YA, Park JS, Park MY, Oh KS, Lee MS, Lim JS, et al. Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett 2011; 585:755-60; PMID:21241697; http://dx.doi.org/10.1016/j.febslet.2011.01.018.
48. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010; 29:6257-66; PMID:20729919; http://dx.doi.org/10.1038/onc.2010.357.
49. Wilson LA, Yamamoto H, Singh G. Role of the transcription factor Ets-1 in cisplatin resistance. Mol Cancer Ther 2004; 3:823-32; PMID:15252143.
50. Khanna A, Mahalingam K, Chakrabarti D, Periyasamy G. Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells. Cell Mol Biol Lett 2011; 16:101-13; PMID:21225469; http://dx.doi. org/10.2478/s11658-010-0043-z.
51. Messeguer X, Escudero R, Farré D, Núñez O, Martínez J, Albà MM. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 2002; 18:333-4; PMID:11847087; http://dx.doi.org/10.1093/bioinformatics/18.2.333.
52. Farré D, Roset R, Huerta M, Adsuara JE, Roselló L, Albà MM, et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res 2003; 31:3651-3; PMID:12824386; http://dx.doi.org/10.1093/nar/ gkg605.
53. Kurachi S, Huo JS, Ameri A, Zhang K, Yoshizawa AC, Kurachi K. An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden. Proc Natl Acad Sci U S A 2009; 106:7921-6; PMID:19416882; http://dx.doi.org/10.1073/ pnas.0902191106.
54. Yang LX, Razzaghi H, Hokanson JE, Kamboh MI. Identification and characterization of a novel 5 bp deletion in a putative insulin response element in the lipoprotein lipase gene. Biochim Biophys Acta 2009; 1791:1057-65; PMID:19563912; http://dx.doi.org/10.1016/j.bbalip.2009.06.003.